0
2022
Next Generation Diabetes Therapy And Drug Delivery Market

Next Generation Diabetes Therapy and Drug Delivery Market

by Product (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), by Demographic (Adult Population (>14years), Child Population (14years)), by Indication (Type 1 Diabetes, Type 2 Diabetes), by End User (Diagnostic/Clinics, ICUs, Home Healthcare): Global Opportunity Analysis and Industry Forecast, 2020-2030

✷  Report Code: A01768
Mar 2022 | Pages: 254
Tables: 176
Charts: 62
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Next Generation Diabetes Therapy And Drug Delivery Market Research, 2030

The global Next Generation Diabetes Therapy and Drug Delivery Market size was valued at $7.1 billion in 2020, and is projected to reach $28.0 billion by 2030, growing at a CAGR of 14.28% from 2021 to 2030. Next generation diabetes therapy and drug delivery devices are used to check the blood glucose levels and deliver insulin into the body. Next Generation Diabetes Therapy and Drug Delivery Market opportunity in oral and inhalable insulin, help introduce insulin into the patient’s body without causing pain and reduce the risk of skin irritation, owing to frequent use of needles. Advancements in diabetes therapy systems, such as insulin patch, continuous glucose monitoring (CGM) system, and artificial pancreas, are frequently used to detect the glucose levels and adjust the insulin levels to manage the change in glucose levels.

The global COVID-19 pandemic has and may continue to have an adverse impact on manufacturing and distribution capabilities of drug delivery devices. In addition, the COVID-19 pandemic and associated shelter-in-place orders restricted ability to initiate, conduct or continue our clinical trials. Delays and disruption in clinical trials could results in delays for expanded FDA clearance or approval of new products

Next Generation Diabetes Therapy and Drug Delivery Market, Next Generation Diabetes Therapy Market, Drug Delivery Market, Next Generation Diabetes Therapy and Drug Delivery Market size, Next Generation Diabetes Therapy and Drug Delivery Market share, Next Generation Diabetes Therapy and Drug Delivery Market trends, Next Generation Diabetes Therapy and Drug Delivery Market forecast, Next Generation Diabetes Therapy and Drug Delivery Market growth, Next Generation Diabetes Therapy and Drug Delivery Market opportunity

 

Increase in prevalence of diabetes, especially type-2 diabetes, due to increase in urbanization, unhealthy diet, and reduced physical activity drive the growth of the next generation diabetes therapy and drug delivery market. In addition, benefits of using these advanced devices over conventional products, rise in the healthcare expenditure, and increase in the disposable income among the diabetic patients are some factors that further boost the growth of the market. However, lack of awareness, cost restrains in the developing regions, and less variability in products are expected to hinder the growth of the market. On the other hand, development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to offer profitable opportunities for the growth of the market during the forecast period.

The Next Generation Diabetes Therapy and Drug Delivery Market growth was slowed by the outbreak of COVID-19 resulted in disrupted workflows in the healthcare sector globally. The COVID-19 pandemic negatively impacted the global next generation diabetes therapy and drug delivery industry market initially in 2020 due to global economic recession led by COVID-19. The implementation of lockdown compromised clinical care of diabetic patients due to service disruption; thereby, having a minimal negative impact on the market.

The global COVID-19 pandemic has and may continue to have an adverse impact on manufacturing and distribution capabilities of drug delivery devices. In addition, the COVID-19 pandemic and associated shelter-in-place orders restricted ability to initiate, conduct or continue our clinical trials. Delays and disruption in clinical trials could results in delays for expanded FDA clearance or approval of new products. For instance, Dexom Inc. has experienced some delays in certain pivotal clinical trials for their next-generation CGM product. This has significantly contributed to decline of the global next generation diabetes therapy and drug delivery market. However, the market is anticipated to witness recovery in 2021, and show stable growth for next generation diabetes therapy and drug delivery market in the coming future. For instance, in April 2020, Dexom inc. provided CGM devices and support to users to enable real-time remote patient monitoring in hospitals and other healthcare facilities, to support COVID-19 healthcare related efforts.

Next Generation Diabetes Therapy market and drug delivery market is segmented on the basis of product, demographic, indication, end user, and region. On the basis of product, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. On the basis of demographic, it is categorized into adult population (>14 years) and child population (≤14 years). On the basis of indication, it is divided into type 1 diabetes and type 2 diabetes.  By end user, the Next Generation Diabetes Therapy and Drug Delivery Market opportunity is classified into diagnostics/clinics, ICUs, and home healthcare. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Next Generation Diabetes Therapy and Drug Delivery Market

Product Review

By product, the market is segmented into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. The CGM systems dominated the global market in 2020, and is expected to remain dominant for Next Generation Diabetes Therapy and Drug Delivery Market forecast. This is attributed to advantages of these systems as compared to conventional diabetic products such as ease of usage and efficient & early detection of change in blood glucose levels.

Next Generation Diabetes Therapy and Drug Delivery Market

Demographic Review

By demographic, the market is segregated into adult population (>14 years) and child population (≤14 years). The adult population segment dominated the global market in 2020, and is anticipated to continue this trend during the forecast period owing to increase in prevalence of diabetes in adult population due to unhealthy lifestyle.

Next Generation Diabetes Therapy and Drug Delivery Market

Indication Review

By indication, the market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes dominated the global market in 2020, and is expected to remain dominant during the forecast period. This is attributed to increase in cases of type-2 diabetic due to increase in urbanization, unhealthy diet, and reduced physical activity.

Next Generation Diabetes Therapy and Drug Delivery Market

End User Review

By end user, the market is classified into diagnostics/clinics, ICUs, and home healthcare. The diagnostics/clinics dominated the global market in 2020, and is anticipated to continue this trend during the forecast period, owing to increase in procurement of the products from diagnostics and clinics by diabetic patients.

Next Generation Diabetes Therapy and Drug Delivery Market

Region Review

The next generation diabetes therapy and drug delivery market in Asia-Pacific is witnessing significant growth, owing to rise in number of diagnostic centers for diabetes, and presence of a large diabetic patient population base in developing countries, such as India and China. In addition, rise in the healthcare expenditure for diabetes and increase in awareness about the benefits of using next generation diabetic products, such as better management of blood glucose level are projected to fuel the market growth in Asia-Pacific.

The Next Generation Diabetes Therapy and Drug Delivery Market share of key market players are profiled in the report include, Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the next generation diabetes therapy and drug delivery market analysis from 2020 to 2030 to identify the prevailing next generation diabetes therapy and drug delivery market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the next generation diabetes therapy and drug delivery market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global next generation diabetes therapy and drug delivery market trends, key players, market segments, application areas, and market growth strategies.

Next Generation Diabetes Therapy and Drug Delivery Market Report Highlights

Aspects Details
By Product
  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patches
  • CGM Systems
  • Artificial Pancreas
By Demographic
  • Adult Population (>14years)
  • Child Population (14years)
By Indication
  • Type 1 Diabetes
  • Type 2 Diabetes
By End User
  • Diagnostic/Clinics
  • ICUs
  • Home Healthcare
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Dexcom, Inc, Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Sanofi S.A., Glysens Incorporated, MannKind Corporation, Johnson & Johnson, Abbott laboratories, Senseonics Holdings, Inc.
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Inhalable Insulin

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Oral Insulin

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Insulin Patches

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 CGM Systems

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

    • 4.6 Artificial Pancreas

      • 4.6.1 Key market trends, growth factors and opportunities

      • 4.6.2 Market size and forecast, by region

      • 4.6.3 Market analysis by country

  • CHAPTER 5: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Adult Population (>14years)

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Child Population (14years)

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

  • CHAPTER 6: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Type 1 Diabetes

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Type 2 Diabetes

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

  • CHAPTER 7: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 Diagnostic/Clinics

      • 7.2.1 Key market trends, growth factors and opportunities

      • 7.2.2 Market size and forecast, by region

      • 7.2.3 Market analysis by country

    • 7.3 ICUs

      • 7.3.1 Key market trends, growth factors and opportunities

      • 7.3.2 Market size and forecast, by region

      • 7.3.3 Market analysis by country

    • 7.4 Home Healthcare

      • 7.4.1 Key market trends, growth factors and opportunities

      • 7.4.2 Market size and forecast, by region

      • 7.4.3 Market analysis by country

  • CHAPTER 8: NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION

    • 8.1 Overview

      • 8.1.1 Market size and forecast

    • 8.2 North America

      • 8.2.1 Key trends and opportunities

      • 8.2.2 North America Market size and forecast, by Product

      • 8.2.3 North America Market size and forecast, by Demographic

      • 8.2.4 North America Market size and forecast, by Indication

      • 8.2.5 North America Market size and forecast, by End User

      • 8.2.6 North America Market size and forecast, by country

        • 8.2.6.1 U.S.
          • 8.2.6.1.1 Market size and forecast, by Product
          • 8.2.6.1.2 Market size and forecast, by Demographic
          • 8.2.6.1.3 Market size and forecast, by Indication
          • 8.2.6.1.4 Market size and forecast, by End User
        • 8.2.6.2 Canada
          • 8.2.6.2.1 Market size and forecast, by Product
          • 8.2.6.2.2 Market size and forecast, by Demographic
          • 8.2.6.2.3 Market size and forecast, by Indication
          • 8.2.6.2.4 Market size and forecast, by End User
        • 8.2.6.3 Mexico
          • 8.2.6.3.1 Market size and forecast, by Product
          • 8.2.6.3.2 Market size and forecast, by Demographic
          • 8.2.6.3.3 Market size and forecast, by Indication
          • 8.2.6.3.4 Market size and forecast, by End User
    • 8.3 Europe

      • 8.3.1 Key trends and opportunities

      • 8.3.2 Europe Market size and forecast, by Product

      • 8.3.3 Europe Market size and forecast, by Demographic

      • 8.3.4 Europe Market size and forecast, by Indication

      • 8.3.5 Europe Market size and forecast, by End User

      • 8.3.6 Europe Market size and forecast, by country

        • 8.3.6.1 Germany
          • 8.3.6.1.1 Market size and forecast, by Product
          • 8.3.6.1.2 Market size and forecast, by Demographic
          • 8.3.6.1.3 Market size and forecast, by Indication
          • 8.3.6.1.4 Market size and forecast, by End User
        • 8.3.6.2 France
          • 8.3.6.2.1 Market size and forecast, by Product
          • 8.3.6.2.2 Market size and forecast, by Demographic
          • 8.3.6.2.3 Market size and forecast, by Indication
          • 8.3.6.2.4 Market size and forecast, by End User
        • 8.3.6.3 U.K.
          • 8.3.6.3.1 Market size and forecast, by Product
          • 8.3.6.3.2 Market size and forecast, by Demographic
          • 8.3.6.3.3 Market size and forecast, by Indication
          • 8.3.6.3.4 Market size and forecast, by End User
        • 8.3.6.4 Italy
          • 8.3.6.4.1 Market size and forecast, by Product
          • 8.3.6.4.2 Market size and forecast, by Demographic
          • 8.3.6.4.3 Market size and forecast, by Indication
          • 8.3.6.4.4 Market size and forecast, by End User
        • 8.3.6.5 Spain
          • 8.3.6.5.1 Market size and forecast, by Product
          • 8.3.6.5.2 Market size and forecast, by Demographic
          • 8.3.6.5.3 Market size and forecast, by Indication
          • 8.3.6.5.4 Market size and forecast, by End User
        • 8.3.6.6 Rest of Europe
          • 8.3.6.6.1 Market size and forecast, by Product
          • 8.3.6.6.2 Market size and forecast, by Demographic
          • 8.3.6.6.3 Market size and forecast, by Indication
          • 8.3.6.6.4 Market size and forecast, by End User
    • 8.4 Asia-Pacific

      • 8.4.1 Key trends and opportunities

      • 8.4.2 Asia-Pacific Market size and forecast, by Product

      • 8.4.3 Asia-Pacific Market size and forecast, by Demographic

      • 8.4.4 Asia-Pacific Market size and forecast, by Indication

      • 8.4.5 Asia-Pacific Market size and forecast, by End User

      • 8.4.6 Asia-Pacific Market size and forecast, by country

        • 8.4.6.1 China
          • 8.4.6.1.1 Market size and forecast, by Product
          • 8.4.6.1.2 Market size and forecast, by Demographic
          • 8.4.6.1.3 Market size and forecast, by Indication
          • 8.4.6.1.4 Market size and forecast, by End User
        • 8.4.6.2 Japan
          • 8.4.6.2.1 Market size and forecast, by Product
          • 8.4.6.2.2 Market size and forecast, by Demographic
          • 8.4.6.2.3 Market size and forecast, by Indication
          • 8.4.6.2.4 Market size and forecast, by End User
        • 8.4.6.3 India
          • 8.4.6.3.1 Market size and forecast, by Product
          • 8.4.6.3.2 Market size and forecast, by Demographic
          • 8.4.6.3.3 Market size and forecast, by Indication
          • 8.4.6.3.4 Market size and forecast, by End User
        • 8.4.6.4 Australia
          • 8.4.6.4.1 Market size and forecast, by Product
          • 8.4.6.4.2 Market size and forecast, by Demographic
          • 8.4.6.4.3 Market size and forecast, by Indication
          • 8.4.6.4.4 Market size and forecast, by End User
        • 8.4.6.5 South Korea
          • 8.4.6.5.1 Market size and forecast, by Product
          • 8.4.6.5.2 Market size and forecast, by Demographic
          • 8.4.6.5.3 Market size and forecast, by Indication
          • 8.4.6.5.4 Market size and forecast, by End User
        • 8.4.6.6 Rest of Asia-Pacific
          • 8.4.6.6.1 Market size and forecast, by Product
          • 8.4.6.6.2 Market size and forecast, by Demographic
          • 8.4.6.6.3 Market size and forecast, by Indication
          • 8.4.6.6.4 Market size and forecast, by End User
    • 8.5 LAMEA

      • 8.5.1 Key trends and opportunities

      • 8.5.2 LAMEA Market size and forecast, by Product

      • 8.5.3 LAMEA Market size and forecast, by Demographic

      • 8.5.4 LAMEA Market size and forecast, by Indication

      • 8.5.5 LAMEA Market size and forecast, by End User

      • 8.5.6 LAMEA Market size and forecast, by country

        • 8.5.6.1 Brazil
          • 8.5.6.1.1 Market size and forecast, by Product
          • 8.5.6.1.2 Market size and forecast, by Demographic
          • 8.5.6.1.3 Market size and forecast, by Indication
          • 8.5.6.1.4 Market size and forecast, by End User
        • 8.5.6.2 Saudi Arabia
          • 8.5.6.2.1 Market size and forecast, by Product
          • 8.5.6.2.2 Market size and forecast, by Demographic
          • 8.5.6.2.3 Market size and forecast, by Indication
          • 8.5.6.2.4 Market size and forecast, by End User
        • 8.5.6.3 South Africa
          • 8.5.6.3.1 Market size and forecast, by Product
          • 8.5.6.3.2 Market size and forecast, by Demographic
          • 8.5.6.3.3 Market size and forecast, by Indication
          • 8.5.6.3.4 Market size and forecast, by End User
        • 8.5.6.4 Rest of LAMEA
          • 8.5.6.4.1 Market size and forecast, by Product
          • 8.5.6.4.2 Market size and forecast, by Demographic
          • 8.5.6.4.3 Market size and forecast, by Indication
          • 8.5.6.4.4 Market size and forecast, by End User
  • CHAPTER 9: COMPANY LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top winning strategies

    • 9.3. Product Mapping of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Key developments

  • CHAPTER 10: COMPANY PROFILES

    • 10.1 Abbott laboratories

      • 10.1.1 Company overview

      • 10.1.2 Company snapshot

      • 10.1.3 Operating business segments

      • 10.1.4 Product portfolio

      • 10.1.5 Business performance

      • 10.1.6 Key strategic moves and developments

    • 10.2 Dexcom, Inc

      • 10.2.1 Company overview

      • 10.2.2 Company snapshot

      • 10.2.3 Operating business segments

      • 10.2.4 Product portfolio

      • 10.2.5 Business performance

      • 10.2.6 Key strategic moves and developments

    • 10.3 Eli Lilly and Company

      • 10.3.1 Company overview

      • 10.3.2 Company snapshot

      • 10.3.3 Operating business segments

      • 10.3.4 Product portfolio

      • 10.3.5 Business performance

      • 10.3.6 Key strategic moves and developments

    • 10.4 Glysens Incorporated

      • 10.4.1 Company overview

      • 10.4.2 Company snapshot

      • 10.4.3 Operating business segments

      • 10.4.4 Product portfolio

      • 10.4.5 Business performance

      • 10.4.6 Key strategic moves and developments

    • 10.5 Johnson & Johnson

      • 10.5.1 Company overview

      • 10.5.2 Company snapshot

      • 10.5.3 Operating business segments

      • 10.5.4 Product portfolio

      • 10.5.5 Business performance

      • 10.5.6 Key strategic moves and developments

    • 10.6 MannKind Corporation

      • 10.6.1 Company overview

      • 10.6.2 Company snapshot

      • 10.6.3 Operating business segments

      • 10.6.4 Product portfolio

      • 10.6.5 Business performance

      • 10.6.6 Key strategic moves and developments

    • 10.7 Medtronic plc

      • 10.7.1 Company overview

      • 10.7.2 Company snapshot

      • 10.7.3 Operating business segments

      • 10.7.4 Product portfolio

      • 10.7.5 Business performance

      • 10.7.6 Key strategic moves and developments

    • 10.8 Novo Nordisk A/S

      • 10.8.1 Company overview

      • 10.8.2 Company snapshot

      • 10.8.3 Operating business segments

      • 10.8.4 Product portfolio

      • 10.8.5 Business performance

      • 10.8.6 Key strategic moves and developments

    • 10.9 Sanofi S.A.

      • 10.9.1 Company overview

      • 10.9.2 Company snapshot

      • 10.9.3 Operating business segments

      • 10.9.4 Product portfolio

      • 10.9.5 Business performance

      • 10.9.6 Key strategic moves and developments

    • 10.10 Senseonics Holdings, Inc.

      • 10.10.1 Company overview

      • 10.10.2 Company snapshot

      • 10.10.3 Operating business segments

      • 10.10.4 Product portfolio

      • 10.10.5 Business performance

      • 10.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
    TABLE 2. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INHALABLE INSULIN, BY REGION , 2020-2030,($MILLION)
    TABLE 3. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INHALABLE INSULIN BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ORAL INSULIN, BY REGION , 2020-2030,($MILLION)
    TABLE 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ORAL INSULIN BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR INSULIN PATCHES, BY REGION , 2020-2030,($MILLION)
    TABLE 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET INSULIN PATCHES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CGM SYSTEMS, BY REGION , 2020-2030,($MILLION)
    TABLE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CGM SYSTEMS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 10. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ARTIFICIAL PANCREAS, BY REGION , 2020-2030,($MILLION)
    TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ARTIFICIAL PANCREAS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 12. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
    TABLE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ADULT POPULATION (>14YEARS), BY REGION , 2020-2030,($MILLION)
    TABLE 14. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ADULT POPULATION (>14YEARS) BY COUNTRY, 2020-2030,($MILLION)
    TABLE 15. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR CHILD POPULATION (14YEARS), BY REGION , 2020-2030,($MILLION)
    TABLE 16. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET CHILD POPULATION (14YEARS) BY COUNTRY, 2020-2030,($MILLION)
    TABLE 17. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
    TABLE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 1 DIABETES, BY REGION , 2020-2030,($MILLION)
    TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 1 DIABETES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 20. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR TYPE 2 DIABETES, BY REGION , 2020-2030,($MILLION)
    TABLE 21. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET TYPE 2 DIABETES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 22. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 23. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR DIAGNOSTIC/CLINICS, BY REGION , 2020-2030,($MILLION)
    TABLE 24. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET DIAGNOSTIC/CLINICS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 25. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR ICUS, BY REGION , 2020-2030,($MILLION)
    TABLE 26. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET ICUS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 27. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET REVENUE, FOR HOME HEALTHCARE, BY REGION , 2020-2030,($MILLION)
    TABLE 28. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET HOME HEALTHCARE BY COUNTRY, 2020-2030,($MILLION)
    TABLE 29. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 30. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
    TABLE 31. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
    TABLE 32. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
    TABLE 33. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 34. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 35. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 36. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 37. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 38. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 39. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 40. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 41. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 42. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 43. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 44. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 45. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 46. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 47. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
    TABLE 48. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
    TABLE 49. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
    TABLE 50. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 51. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 52. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 53. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 54. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 55. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 56. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 57. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 58. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 59. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 60. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 61. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 62. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 63. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 64. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 65. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 66. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 67. ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 68. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 69. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 70. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 71. SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 72. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 73. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 74. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 75. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 76. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
    TABLE 77. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
    TABLE 78. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
    TABLE 79. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 80. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 81. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 82. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 83. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 84. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 85. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 86. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 87. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 88. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 89. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 90. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 91. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 92. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 93. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 94. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 95. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 96. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 97. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 98. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 99. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 100. SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 101. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 102. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 103. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 104. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 105. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2020-2030,($MILLION)
    TABLE 106. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHIC, 2020-2030,($MILLION)
    TABLE 107. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2020-2030,($MILLION)
    TABLE 108. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2020-2030,($MILLION)
    TABLE 109. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 110. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 111. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 112. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 113. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 114. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 115. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 116. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 117. SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 118. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 119. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 120. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 121. SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 122. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY PRODUCT 2020-2030,($MILLION)
    TABLE 123. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY DEMOGRAPHIC 2020-2030,($MILLION)
    TABLE 124. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY INDICATION 2020-2030,($MILLION)
    TABLE 125. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY END USER 2020-2030,($MILLION)
    TABLE 126.ABBOTT LABORATORIES: COMPANY SNAPSHOT
    TABLE 127.ABBOTT LABORATORIES: OPERATING SEGMENTS
    TABLE 128.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
    TABLE 129.ABBOTT LABORATORIES: NET SALES,
    TABLE 130.ABBOTT LABORATORIES: KEY STRATERGIES
    TABLE 131.DEXCOM, INC: COMPANY SNAPSHOT
    TABLE 132.DEXCOM, INC: OPERATING SEGMENTS
    TABLE 133.DEXCOM, INC: PRODUCT PORTFOLIO
    TABLE 134.DEXCOM, INC: NET SALES,
    TABLE 135.DEXCOM, INC: KEY STRATERGIES
    TABLE 136.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 137.ELI LILLY AND COMPANY: OPERATING SEGMENTS
    TABLE 138.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 139.ELI LILLY AND COMPANY: NET SALES,
    TABLE 140.ELI LILLY AND COMPANY: KEY STRATERGIES
    TABLE 141.GLYSENS INCORPORATED: COMPANY SNAPSHOT
    TABLE 142.GLYSENS INCORPORATED: OPERATING SEGMENTS
    TABLE 143.GLYSENS INCORPORATED: PRODUCT PORTFOLIO
    TABLE 144.GLYSENS INCORPORATED: NET SALES,
    TABLE 145.GLYSENS INCORPORATED: KEY STRATERGIES
    TABLE 146.JOHNSON & JOHNSON: COMPANY SNAPSHOT
    TABLE 147.JOHNSON & JOHNSON: OPERATING SEGMENTS
    TABLE 148.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
    TABLE 149.JOHNSON & JOHNSON: NET SALES,
    TABLE 150.JOHNSON & JOHNSON: KEY STRATERGIES
    TABLE 151.MANNKIND CORPORATION: COMPANY SNAPSHOT
    TABLE 152.MANNKIND CORPORATION: OPERATING SEGMENTS
    TABLE 153.MANNKIND CORPORATION: PRODUCT PORTFOLIO
    TABLE 154.MANNKIND CORPORATION: NET SALES,
    TABLE 155.MANNKIND CORPORATION: KEY STRATERGIES
    TABLE 156.MEDTRONIC PLC: COMPANY SNAPSHOT
    TABLE 157.MEDTRONIC PLC: OPERATING SEGMENTS
    TABLE 158.MEDTRONIC PLC: PRODUCT PORTFOLIO
    TABLE 159.MEDTRONIC PLC: NET SALES,
    TABLE 160.MEDTRONIC PLC: KEY STRATERGIES
    TABLE 161.NOVO NORDISK A/S: COMPANY SNAPSHOT
    TABLE 162.NOVO NORDISK A/S: OPERATING SEGMENTS
    TABLE 163.NOVO NORDISK A/S: PRODUCT PORTFOLIO
    TABLE 164.NOVO NORDISK A/S: NET SALES,
    TABLE 165.NOVO NORDISK A/S: KEY STRATERGIES
    TABLE 166.SANOFI S.A.: COMPANY SNAPSHOT
    TABLE 167.SANOFI S.A.: OPERATING SEGMENTS
    TABLE 168.SANOFI S.A.: PRODUCT PORTFOLIO
    TABLE 169.SANOFI S.A.: NET SALES,
    TABLE 170.SANOFI S.A.: KEY STRATERGIES
    TABLE 171.SENSEONICS HOLDINGS, INC.: COMPANY SNAPSHOT
    TABLE 172.SENSEONICS HOLDINGS, INC.: OPERATING SEGMENTS
    TABLE 173.SENSEONICS HOLDINGS, INC.: PRODUCT PORTFOLIO
    TABLE 174.SENSEONICS HOLDINGS, INC.: NET SALES,
    TABLE 175.SENSEONICS HOLDINGS, INC.: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET SEGMENTATION
    FIGURE 2.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030
    FIGURE 3.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 11.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY PRODUCT,2020(%)
    FIGURE 12.COMPARATIVE SHARE ANALYSIS OF INHALABLE INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ORAL INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF INSULIN PATCHES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CGM SYSTEMS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ARTIFICIAL PANCREAS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 17.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY DEMOGRAPHIC,2020(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ADULT POPULATION (>14YEARS) NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHILD POPULATION (14YEARS) NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 20.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY INDICATION,2020(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF TYPE 1 DIABETES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF TYPE 2 DIABETES NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 23.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,BY END USER,2020(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC/CLINICS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF ICUS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOME HEALTHCARE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030(%)
    FIGURE 27.NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET BY REGION,2020
    FIGURE 28.U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 29.CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 30.MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 31.GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 32.FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 33.U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 34.ITALY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 35.SPAIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 36.REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 37.CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 38.JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 39.INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 40.AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 41.SOUTH KOREA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 42.REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 43.BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 44.SAUDI ARABIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 45.SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 46.REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,2020-2030($MILLION)
    FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 50.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 51.COMPETITIVE DASHBOARD
    FIGURE 52.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 53.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
    FIGURE 54.DEXCOM, INC.: NET SALES ,($MILLION)
    FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
    FIGURE 56.GLYSENS INCORPORATED.: NET SALES ,($MILLION)
    FIGURE 57.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
    FIGURE 58.MANNKIND CORPORATION.: NET SALES ,($MILLION)
    FIGURE 59.MEDTRONIC PLC.: NET SALES ,($MILLION)
    FIGURE 60.NOVO NORDISK A/S.: NET SALES ,($MILLION)
    FIGURE 61.SANOFI S.A..: NET SALES ,($MILLION)
    FIGURE 62.SENSEONICS HOLDINGS, INC..: NET SALES ,($MILLION)

 
 

The utilization of next generation diabetes therapy and drug delivery devices is expected to increase due to surge in the global incidence rate of diabetes. There have been remarkable technological advancements related to next generation diabetes therapy and drug delivery devices to provide advanced treatment options for patients suffering from diabetes. In addition, North America accounted for a majority of the global next generation diabetes therapy and drug delivery market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to rise in the number of diabetic patients, high adoption rate of next generation diabetic products, emergence of more advanced products, presence of major key players, and development in technology for healthcare in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to rise in R&D for the advancement of diabetic products in the countries of Asia-Pacific, growth in healthcare expenditures, and increase in awareness about the benefits of using next generation diabetic products such as better management of blood glucose level.

Moreover, increase in disposable income among the diabetic patients and technological advancement of next generation diabetic products are some of the driving factors of the market. However, lack of awareness, less variability in products, and cost restrains in the developing regions are expected to hamper the market growth. Presently, the demand for oral & inhalable insulin has increased as these are painless mode of insulin delivery and reduce the risk of skin irritation caused due to needles. They are expected to replace injectable insulin, owing to their ease of using with improved efficiency. Moreover, majority of the next generation diabetes therapy and drug delivery devices manufacturers and distributors have focused on expanding their presence in the emerging economies, such Asia-Pacific and LAMEA.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of next generation diabetes therapy and drug delivery market is $7,080.6 million in 2020.

A. The forcast period for next generation diabetes therapy and drug delivery market is 2021 to 2030

A. The market value of next generation diabetes therapy and drug delivery market in 2030 is $28044.23 million.

A. The base year is 2020 in next generation diabetes therapy and drug delivery market

A. Top companies such as Abbott Laboratories, Medtronic, Inc., Sanofi S.A., Novo Nordisk, MannKind Corporation, Eli Lilly and Company, Dexcom, Inc., Senseonics Holding, Inc., Glysens Incorporated, and Johnson & Johnson. held a high market position in 2020.

A. The CGM system segment is the most influencing segment owing to advantages of these systems as compared to conventional diabetic products such as ease of usage and efficient & early detection of change in blood glucose levels.

A. Increase in prevalence of diabetes, especially type-2 diabetes, due to increase in urbanization, unhealthy diet, and reduced physical activity drive the growth of the next generation diabetes therapy and drug delivery market. In addition, benefits of using these advanced devices over conventional products, rise in the healthcare expenditure, and increase in the disposable income among the diabetic patients are some factors that further boost the growth of the market.

A. Asia-Pacific is expected to experience the growth rate of 16.29 % during the forecast period, owing to rise in number of diagnostic centers for diabetes, and presence of a large diabetic patient population base in developing countries, such as India and China.

A. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients.

A. Next generation diabetes therapy and drug delivery devices are used to check the blood glucose levels and deliver insulin into the body.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Next Generation Diabetes Therapy And Drug Delivery Market

Start reading instantly.
This Report and over 68,399+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,565
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Data Pack
  • $3,961
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Single User
  • $5,540
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Five Users
  • $6,654
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Enterprise
    License/PDF

  • $10,280
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2023 - Mar 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers